Blog
RSS FeedPosted by Michael Wonder on 03 May 2021
TLV reconsiders subsidy for eleven TNF alfa inhibitors included in the high-cost protection
30 April 2021 - Today, eleven subcutaneous TNF-alpha inhibitors are included in the high-cost protection. ...
Posted by Michael Wonder on 21 Apr 2021
Additional analysis of Luxturna in the treatment of visual impairment caused by hereditary eye disease
21 April 2021 - TLV has made a supplementary analysis to the previous evaluation of Luxturna, as Novartis has submitted new ...
Posted by Michael Wonder on 21 Apr 2021
Health economic assessment of Qarziba in patients with high-risk neuroblastoma
21 April 2021 - TLV has produced a health economic assessment for the regions for the drug Qarziba (dinutuximab beta). ...
Posted by Michael Wonder on 20 Apr 2021
Health economic assessment of Darzalex in multiple myeloma
19 April 2021 - TLV has produced a health economic assessment for the regions for the drug Darzalex in combination with ...
Posted by Michael Wonder on 14 Apr 2021
Patient and public involvement in health technology assessment: a new dawn?
12 April 2021 - Patient and public involvement and engagement have become increasingly embedded in health technology assessment over the last ...
Posted by Michael Wonder on 29 Mar 2021
TLV subsidises melatonin for children and adolescents with ADHD
26 March 2021 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, grants a subsidy for the drug Melatonin AGB ...
Posted by Michael Wonder on 25 Mar 2021
Too high price for drugs for cystic fibrosis
25 March 2021 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, says no to subsidising the drugs Kaftrio and Kalydeco ...
Posted by Michael Wonder on 15 Mar 2021
Health economic assessment of Zolgensma in spinal muscular atrophy
12 March 2021 - TLV has produced a health economic assessment for the regions for Zolgensma (onasemnogene abeparvovec) in the treatment ...
Posted by Michael Wonder on 14 Mar 2021
Discounting in economic evaluation of health care interventions: what about the risk term?
13 March 2021 - Results from economic evaluations of long-term outcomes are strongly dependent on the chosen discount rate. ...
Posted by Michael Wonder on 17 Feb 2021
TLV is tasked with reducing costs for medicines
16 February 2021 - The Government has commissioned the Swedish Dental and Pharmaceutical Benefits Agency, TLV, to implement measures to reduce ...
Posted by Michael Wonder on 27 Jan 2021
On the role of cost effectiveness thresholds in health care priority setting
25 January 2021 - In the past few years, empirical estimates of the marginal cost at which health care produces a ...
Posted by Michael Wonder on 18 Dec 2020
Medicines for hepatitis C remain in the high-cost protection after TLV's reconsideration
18 December 2020 - During the autumn, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, reconsidered the subsidy of the hepatitis ...
Posted by Michael Wonder on 13 Dec 2020
Reimbursement from pharmaceutical companies decreases by 288 million
11 December 2020 - The rebate from side agreements between regions and pharmaceutical companies is estimated according to the forecast ...
Posted by Michael Wonder on 08 Dec 2020
TLV wants to go further with combination treatments in the field of cancer
7 December 2020 - Part of the solution for more patients to have access to combination treatments may be to create ...
Posted by Michael Wonder on 07 Dec 2020
New report on TLV's medical technology assignment
3 December 2020 - In a new report, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, reports on the work that ...